# Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

* Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis.
* The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial.
* IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging.
* A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones.
* Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility.

 Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

 Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/why-izotropic-corp-cse-izo-otcqb-izozf-is-one-to-watch/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/izotropic-revolutionizes-breast-cancer-imaging-with-exclusive-breast-ct-tech/523cd949aa3ba439f25f7ba170815711) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1mclbib/izotropic_revolutionizes_breast_cancer_imaging/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/29/quizPUc8.webp)